A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.

@article{Sereno2015ASR,
  title={A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.},
  author={Maria Jane Cruz de Melo Sereno and V{\'i}ctor Moreno and Juan Moreno Rubio and C{\'e}sar G{\'o}mez-Raposo and Sagrario Garc{\'i}a S{\'a}nchez and Rebeca Hern{\'a}ndez Jusdado and Sandra Falagan and Francisco Zambrana T{\'e}bar and Enrique Casado S{\'a}enz},
  journal={Anti-cancer drugs},
  year={2015},
  volume={26 9},
  pages={1004-7}
}
Lung adenocarcinoma includes recurrent activating oncogenic mutations (EGFR, EML4-ALK, ROS1) that have been associated with response to EGFR and ALK inhibitors. Platinum-based chemotherapy is the standard therapy for non-oncodrivers population. Sorafenib is a small molecule that blocks the activation of C-RAF, B-RAF, c-KIT, FLT-3, RET, VEGFR-2, VEGFR-3 and PDGFR approved for advanced renal cell and hepatocellular carcinoma (b, c). Many studies have evaluated sorafenib in advanced non-small-cell… CONTINUE READING